A world-first artificial cell can chase chemicals using only a membrane, an enzyme, and a pore—no DNA or motors needed.

GLP-1 drugs for diabetes and weight loss are difficult for some people to inject weekly. A new slow-release gel, tested in rats, could help.

Two prominent industrial process technology manufacturers are set to combine in a deal valued at approximately $19 billion. Chart Industries and Flowserve Corporation announced June 4 that they’ve ...